A new blood test, named the Galleri liquid biopsy, has been introduced to the market, offering the potential to detect early signs of cancer. Priced at $949, the test claims to screen for over 50 types of cancers by identifying a common cancer signal present in DNA fragments released by tumors into the bloodstream. Since its launch in June 2021, Grail, the company behind Galleri and a subsidiary of gene-sequencing firm Illumina, has reported sales of more than 130,000 prescription-only tests. However, the medical community appears divided on the test’s current utility, with some expressing excitement about its potential, while…
Author: Abhay Panchal
GigXR, Inc., a leading provider of holographic healthcare training, has announced a collaboration with the Yong Loo Lin School of Medicine at the National University of Singapore (NUS Medicine). This partnership aims to introduce a new gastrointestinal module for the HoloScenarios application, designed to enhance the training of medical and nursing students in diagnosing and treating acute gastrointestinal diseases. The HoloScenarios: Gastrointestinal module offers evidence-based clinical simulations featuring hyperrealistic holographic simulated patients and medical equipment, accessible from anywhere globally. Key Highlights:
In 2023, prior authorization has emerged as a significant concern in the field of gastroenterology. Dr. Benjamin Levy III, a gastroenterologist at the University of Chicago Medicine, discussed the challenges posed by prior authorizations in an interview with Becker’s. He highlighted several key points: In summary, while prior authorizations aim to ensure appropriate care, they also introduce administrative challenges that can hinder timely patient care and increase costs.
Artificial intelligence (AI) already is making a difference in healthcare by helping medical professionals interpret tests, clarify diagnoses and identify the most effective treatment approaches to a range of diseases. As Cedars-Sinai explores new uses of AI, it is balancing the rapid development of this emerging technology with responsible and ethical implementation. “AI systems have the power to transform healthcare,” said Mike Thompson, vice president of Enterprise Data Intelligence at Cedars-Sinai. “If implemented properly and responsibly, AI can be deployed to enhance patient experience, improve population health, reduce costs and improve the work life of healthcare providers.” Thompson sat down…
A next-generation, multitarget stool DNA test, known as the next-generation Cologuard, has demonstrated a 94% sensitivity and 91% specificity in detecting colorectal cancer, surpassing the performance of fecal immunochemical testing (FIT). Thomas F. Imperiale, MD, from Indiana University Medical Center, highlighted that this version of Cologuard differs from FIT due to its unique markers, which are all methylated DNA markers. In the BLUE-C study, which involved 26,758 participants, the next-generation Cologuard showed a higher likelihood of detecting cancer (94% vs. 67%) and precancerous lesions (43% vs. 23%) compared to FIT. Imperiale emphasized the significance of the improved specificity, which is…
Motus GI Holdings, Inc., a medical technology company focused on enhancing endoscopic outcomes, has announced that it has secured clearance from the U.S. Food and Drug Administration (FDA) for its new Pure-Vu EVS Gastro and Gen 4 Colon system. This clearance paves the way for the company to tap into the upper gastrointestinal (GI) market, addressing the needs of patients with upper GI bleeds, a condition with high mortality rates. The new Pure-Vu systems offer significant improvements over previous models, aiming to provide better visualization in both the upper and lower GI tracts. These advancements include a more powerful suction…
Microsoft and Google have recently introduced new features for their healthcare cloud products, aiming to consolidate data from diverse sources such as EHRs, labs, revenue cycles, and more. This integration will enable healthcare organizations to derive insights from various datasets or establish standardized processes. Key Points:
American patients are divided regarding their comfort with the application of artificial intelligence (AI) in their healthcare experiences. A survey conducted by Propeller Insights on behalf of Carta Healthcare revealed the following:
The gastroenterology industry is witnessing rapid advancements with the integration of artificial intelligence and innovative technologies, offering specialists novel methods to care for and treat patients. Here are five groundbreaking GI-industry devices:
An app-based digital therapeutic has shown significant efficacy in reducing symptoms and enhancing the quality of life, work productivity, and health literacy among patients with irritable bowel syndrome (IBS). These findings are from the ColoFuture Study, presented at the UEG Week 2023. Key Findings: